Brand Insights - Thought Leadership | Paid Program
How commercial teams can benefit from a more scientifically rigorous approach to insights generation
Commercial leaders across biopharmaceutical companies of all sizes will invest millions of dollars each month on developing insights to inform their understanding of the market and their own brand ambition and to determine where to play and how to win. And it is no wonder: The pressure to succeed at moments of truth like launch has never been higher, and it is well understood that investing more upfront in insights and strategy will better position a brand once it hits the market. This has led to ever-growing insights budgets to invest in increasingly large-sample qualitative interviews with every form and segment of healthcare provider, institutional decision-maker, payer, patient, caregiver, and patient advocacy group.
The voice of the customer is crucial, but too often the vast majority of insights investment is spent on deductive research and exploratory insights generation—going in with a broad question (or no question) and getting appropriately lackluster insights that inform a general point of view, but nothing deep enough that offers a brand the true opportunity to step up and do something different that matters in the market.
Unsurprisingly, there is a better way. By taking a more scientifically rigorous approach to insights generation, commercial teams can make their brand insights investment pay off by developing a deeper customer understanding and realizing potential cost savings.
The concept is relatively straightforward and something that our R&D colleagues in the industry live by. It goes back to the simple concept of the scientific method, or what Stanford University characterizes as “systematic observation and experimentation, inductive and deductive reasoning, and the formation and testing of hypotheses and theories.” We can break down the approach based on the three areas of activities associated with the scientific method.
Systematic observation and experimentation
Through systematic observation and experimentation, we leverage our experiences of the market landscape with customers, existing research, analogs, data, and expert perspectives to continually inform and refine hypotheses. Eversana helps clients achieve this is by combining deep industry, therapy area, and brand experience combined with data platforms like ACTICS by Eversana that leverage proprietary artificial intelligence and machine learning technologies to observe trends and run experiments on a continuous basis.
Consider the example of a client team preparing to launch a new brand for the treatment of major depressive disorder (MDD) with a new mechanism of action and mode of administration that would involve new settings of care. Despite the extent of unknowns, we spent resources upfront cataloging insights from analogous launches, developing an understanding from existing customer relationships and rolling research efforts—which allowed for a rolling, systematic cycle of learning that informed more targeted experimentation and insights.
Inductive and deductive reasoning
Next, we need to rebalance the mix between inductive and deductive approaches. Inductive, hypothesis-driven insights projects allow us to get to deeper insights, but it is the fear of experiments “proving us wrong” that appear to limit the willingness to entertain this approach. A mindset shift is required here, celebrating the insights that come from a disciplined experiment—independent of whether the results support or do not support a hypothesis.
Formation & testing of hypotheses, theories
Finally, we must develop the discipline and collaboration techniques to form solid hypotheses as commercial teams. Key questions to challenge our disciplined thinking include:
• Is the idea or concept new enough that we have not tested it before?
• Is it meaningful enough to inform our brand strategic priorities?
• Do we believe we can reasonably test this hypothesis?
The approach outlined above might seem daunting and a shift from the norm, but for those willing to accept the need to try a new approach and employ the scientific method in developing brand insights, the rewards can be enormous.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.